Charles Schwab Investment Management Inc. Boosts Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Charles Schwab Investment Management Inc. raised its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 4.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 577,322 shares of the medical research company's stock after acquiring an additional 24,347 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.18% of Charles River Laboratories International worth $86,899,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Bank of Nova Scotia boosted its position in Charles River Laboratories International by 4.9% during the fourth quarter. Bank of Nova Scotia now owns 5,011 shares of the medical research company's stock worth $925,000 after acquiring an additional 232 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Charles River Laboratories International in the 4th quarter valued at approximately $42,776,000. Sterling Capital Management LLC grew its position in shares of Charles River Laboratories International by 53.8% in the 4th quarter. Sterling Capital Management LLC now owns 3,086 shares of the medical research company's stock valued at $570,000 after buying an additional 1,080 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Charles River Laboratories International in the 4th quarter valued at $539,000. Finally, Canada Post Corp Registered Pension Plan purchased a new position in shares of Charles River Laboratories International in the 4th quarter valued at $114,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Price Performance

CRL stock traded up $0.86 during mid-day trading on Friday, reaching $156.66. 1,038,291 shares of the company traded hands, compared to its average volume of 1,079,568. The company has a fifty day moving average price of $156.87 and a 200-day moving average price of $148.86. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $230.02. The company has a market capitalization of $7.71 billion, a P/E ratio of -117.79, a P/E/G ratio of 5.00 and a beta of 1.48. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.62. The company had revenue of $1.03 billion during the quarter, compared to analysts' expectations of $983.76 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm's revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.80 EPS. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Citigroup upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and raised their price objective for the company from $150.00 to $200.00 in a research note on Wednesday, July 9th. Robert W. Baird lifted their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research report on Thursday, May 8th. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a research report on Wednesday, May 14th. JPMorgan Chase & Co. upped their price target on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Finally, Barclays boosted their target price on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the company an "equal weight" rating in a research note on Thursday, August 7th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of "Hold" and an average target price of $175.69.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 400 shares of the firm's stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $150.04, for a total transaction of $60,016.00. Following the completion of the transaction, the executive vice president owned 24,916 shares in the company, valued at $3,738,396.64. This trade represents a 1.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).